KALRAY
11.5.2023 07:46:32 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL), a leading provider of hardware and software technologies for high-performance, data-centric computing markets, from cloud to edge, is pleased to announce that the IP-CUBE project, led by Kalray, has won the "Technological Maturation and Demonstration of Embedded Artificial Intelligence Solutions" call for projects under the "France Relance 2030 - Future Investments" plan. Kalray's next-generation high-performance, low-power DPU processor is at the heart of the project.
ARTIFICIAL INTELLIGENCE, EDGE COMPUTING, AND SEMICONDUCTORS - MAJOR CHALLENGES FOR THE COMING DECADES
Use cases linked to artificial intelligence (AI) are developing exponentially. Whereas the massive diffusion of AI currently relies heavily on the use of computing resources located in the cloud, there is a growing need for solutions allowing the use of AI in a more reactive, more secure, and less energy hungry way for users. These AI solutions will be deployed in particular in embedded systems as well as local data centers ("edge data centers") that aim to process data closer to where it is generated, as efficiently as possible. This is known as "edge computing", a fast-growing market estimated to be worth several billion Euros1 by 2025 that is comprised of vast areas of the economy such as the telecommunications, new generation of manufacturing, IoT, automotive industry, aerospace, and defense.
However, embedded AI and edge computing require new types of processors and new semiconductor technologies to process and accelerate AI algorithms and meet new technological challenges; high performance, but also low power consumption, low latency, and security.
The IP-CUBE project, led by Kalray, aims to meet these challenges and create the foundations of a French semiconductor ecosystem in the field of edge computing and embedded AI, based on the national leaders in the field, namely Arteris, Kalray, Secure-IC, and Thales.
FINANCING OF STRATEGIC AND SOVEREIGN TECHNOLOGIES
The IP-CUBE project, totaling €36.7M, will directly participate in funding key technology building blocks in this area, particularly Kalray's next-generation Dolomites™ DPU processor for the amount of €10M, Arteris' next-generation NoC (Network-On-Chip), Secure-IC's specialized IP (intellectual property) development for security, and Thales' RISC-V-based low-power component development.
"We are very pleased that the IP-CUBE project has been selected. It will not only allow us to finance a significant part of the development of our 4th generation DPU processor, but also to develop, in collaboration with our partners, the French know-how and technologies in the strategic semiconductor fields around AI applications," said Eric Baissus, CEO of Kalray.
Kalray is the only company in France and Europe to offer DPU (Data Processing Unit) processors, a new type of low-power, high-performance programmable processor, capable of processing data on the fly and multiple applications (AI and others) in parallel, while providing the required security features.
As a pioneer in the field, Kalray has developed a unique expertise and an innovative technology based on its patented MPPA® (Massively Parallel Processor Array) architecture, the cornerstone of its DPU processors and acceleration cards. This technological leadership enables Kalray to offer a serious French and European alternative to the predominantly American or Chinese technology players. At the end of 2022, Kalray announced the signing of a framework contract with a major NASDAQ-listed customer to supply its high-performance DPU cards.
"In the current geopolitical context, the semiconductor industry has become essential, both in terms of production tools and technological know-how for designing processors. France and Europe need production plants, but they also need companies capable of designing the processors that will be manufactured in these plants, and that will be at the heart of tomorrow's markets. We are delighted with the strong support from France through the IP-CUBE project, and the support from Europe through other collaborative projects, such as the EPI (European Processor Initiative), in which Kalray is also participating, to help us achieve our ambition of making Kalray the future European Nvidia," concluded Eric Baissus.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
| ___________________________________ | ||
1 |
McKinsey – AI-related semiconductor market. |
|
NVIDIA: https://blogs.nvidia.com/blog/2019/10/22/what-is-edge-computing/ |
||
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom